An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency
Phase of Trial: Phase IV
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors CSL Behring
- 31 Dec 2018 Status changed from active, no longer recruiting to completed.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Nov 2018 Planned End Date changed from 30 Nov 2018 to 12 Dec 2018.